| Literature DB >> 29427906 |
Elsa Forcellini1, Sophie Boutin1, Carole-Anne Lefebvre1, Elnur Elyar Shayhidin2, Marie-Chloé Boulanger2, Gabrielle Rhéaume2, Xavier Barbeau3, Patrick Lagüe3, Patrick Mathieu2, Jean-François Paquin4.
Abstract
The ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) was recently shown to promote mineralization of the aortic valve, hence, its inhibition represents a significant target. A quinazoline-4-piperidine sulfamide compound (QPS1) has been described as a specific and non-competitive inhibitor of NPP1. We report herein the synthesis and in vitro inhibition studies of novel quinazoline-4-piperidine sulfamide analogues using QPS1 as the lead compound. Of the 26 derivatives prepared, four compounds were found to have Ki < 105 nM against human NPP1.Entities:
Keywords: Calcific aortic valve disease; NPP1 inhibitor; Quinazoline; Sulfamide
Mesh:
Substances:
Year: 2018 PMID: 29427906 DOI: 10.1016/j.ejmech.2018.01.094
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514